Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Disability-Adjusted Life-Years Due to Stroke in Kenya.

Kaduka L, Muniu E, Mbui J, Oduor Owuor C, Gakunga R, Kwasa J, Wabwire S, Okerosi N, Korir A, Remick SC.

Neuroepidemiology. 2019;53(1-2):48-54. doi: 10.1159/000498970. Epub 2019 Apr 15.

PMID:
30986786
2.

Prostate cancer navigation: initial experience and association with time to care.

Serrell EC, Hansen M, Mills G, Perry A, Robbins T, Feinberg M, Remick SC, Beaule L, Hayn M, Kinkead T, Han PKJ, Sammon JD.

World J Urol. 2019 Jun;37(6):1095-1101. doi: 10.1007/s00345-018-2452-y. Epub 2018 Aug 27.

PMID:
30151598
3.

Stroke distribution patterns and characteristics in Kenya's leading public health tertiary institutions: Kenyatta National Hospital and Moi Teaching and Referral Hospital.

Kaduka L, Korir A, Oduor CO, Kwasa J, Mbui J, Wabwire S, Gakunga R, Okerosi N, Opanga Y, Kisiang'ani I, Chepkurui MR, Muniu E, Remick SC.

Cardiovasc J Afr. 2018 Mar/Apr;29(2):68-72. doi: 10.5830/CVJA-2017-046.

4.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

5.

Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.

Chi A, Wen S, Monga M, Almubarak M, He X, Rojanasakul Y, Tse W, Remick SC.

PLoS One. 2016 Sep 9;11(9):e0162453. doi: 10.1371/journal.pone.0162453. eCollection 2016.

6.

MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling.

Park J, Kim S, Joh J, Remick SC, Miller DM, Yan J, Kanaan Z, Chao JH, Krem MM, Basu SK, Hagiwara S, Kenner L, Moriggl R, Bunting KD, Tse W.

Oncotarget. 2016 Jul 12;7(28):43960-43973. doi: 10.18632/oncotarget.9759.

7.

Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study.

Buckle G, Maranda L, Skiles J, Ong'echa JM, Foley J, Epstein M, Vik TA, Schroeder A, Lemberger J, Rosmarin A, Remick SC, Bailey JA, Vulule J, Otieno JA, Moormann AM.

Int J Cancer. 2016 Sep 15;139(6):1231-40. doi: 10.1002/ijc.30170. Epub 2016 May 18.

8.

Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.

Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Little RF, Dunleavy K, Wilson WH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA.

Ann Oncol. 2015 May;26(5):958-66. doi: 10.1093/annonc/mdv036. Epub 2015 Jan 28. Review.

9.

Sorafenib and thyroid cancer.

Park C, Perini J, Farmer RW, Fancy T, Monga M, Remick SC.

Expert Rev Endocrinol Metab. 2014 Nov;9(6):561-570. doi: 10.1586/17446651.2014.960391. Epub 2014 Sep 16.

PMID:
30736194
10.

Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.

Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, Freedman A, Minasian L, Force T, Remick SC.

J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju232. doi: 10.1093/jnci/dju232. Print 2014 Sep.

11.

PSP94, an upstream signaling mediator of prostasin found highly elevated in ovarian cancer.

Ma JX, Yan BX, Zhang J, Jiang BH, Guo Y, Riedel H, Mueller MD, Remick SC, Yu JJ.

Cell Death Dis. 2014 Sep 4;5:e1407. doi: 10.1038/cddis.2014.374.

12.

Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond.

Chi A, Nguyen NP, Welsh JS, Tse W, Monga M, Oduntan O, Almubarak M, Rogers J, Remick SC, Gius D.

Front Oncol. 2014 Jun 20;4:156. doi: 10.3389/fonc.2014.00156. eCollection 2014. Review.

13.

Developing clinical strength-of-evidence approach to define HIV-associated malignancies for cancer registration in Kenya.

Korir A, Mauti N, Moats P, Gurka MJ, Mutuma G, Metheny C, Mwamba PM, Oyiro PO, Fisher M, Ayers LW, Rochford R, Mwanda WO, Remick SC.

PLoS One. 2014 Jan 23;9(1):e85881. doi: 10.1371/journal.pone.0085881. eCollection 2014.

14.

Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin.

Yan BX, Ma JX, Zhang J, Guo Y, Mueller MD, Remick SC, Yu JJ.

Cell Death Dis. 2014 Jan 16;5:e995. doi: 10.1038/cddis.2013.523.

15.

Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies.

Yu JJ, Yang X, Song Q, Mueller MD, Remick SC.

Anticancer Res. 2014 Jan;34(1):455-63. Review.

PMID:
24403501
16.

Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies.

Basu SK, Remick SC, Monga M, Gibson LF.

Clin Exp Metastasis. 2014 Feb;31(2):257-67. doi: 10.1007/s10585-013-9623-4. Epub 2013 Dec 5. Review.

17.

PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer.

Yan BX, Ma JX, Zhang J, Guo Y, Riedel H, Mueller MD, Remick SC, Yu JJ.

Oncogene. 2014 Nov 6;33(45):5288-94. doi: 10.1038/onc.2013.466. Epub 2013 Nov 4.

PMID:
24186202
18.

Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.

Hamadani M, Gibson LF, Remick SC, Wen S, Petros W, Tse W, Brundage KM, Vos JA, Cumpston A, Bunner P, Craig MD.

J Clin Oncol. 2013 Dec 10;31(35):4416-23. doi: 10.1200/JCO.2013.50.8747. Epub 2013 Oct 28.

19.

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.

Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA.

Blood. 2013 Nov 7;122(19):3251-62. doi: 10.1182/blood-2013-04-498964. Epub 2013 Sep 6. Review.

20.

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.

Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC.

Thyroid. 2014 Feb;24(2):232-40. doi: 10.1089/thy.2013.0078. Epub 2013 Sep 10.

PMID:
23721245
21.

Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, Wasman J, Dowlati A, Remick SC.

Thyroid. 2013 May;23(5):600-4. doi: 10.1089/thy.2012.0103. Epub 2013 Apr 18.

22.

Phase I trial of pomalidomide given for patients with advanced solid tumors.

Cooney MM, Nock C, Bokar J, Krishnamurthi S, Gibbons J, Rodal MB, Ness A, Remick SC, Dreicer R, Dowlati A.

Cancer Chemother Pharmacol. 2012 Nov;70(5):755-61. doi: 10.1007/s00280-012-1919-6. Epub 2012 Aug 9.

PMID:
22875080
23.

Declining mammography screening in a state Medicaid Fee-for-Service program: 1999-2008.

Bhanegaonkar A, Madhavan SS, Khanna R, Remick SC.

J Womens Health (Larchmt). 2012 Aug;21(8):821-9. doi: 10.1089/jwh.2011.2748. Epub 2012 May 8.

24.

A comparative investigation of methods for longitudinal data with limits of detection through a case study.

Fu P, Hughes J, Zeng G, Hanook S, Orem J, Mwanda OW, Remick SC.

Stat Methods Med Res. 2016 Feb;25(1):153-66. doi: 10.1177/0962280212444800. Epub 2012 Apr 13.

PMID:
22504231
25.

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH.

Am Heart J. 2012 Feb;163(2):156-63. doi: 10.1016/j.ahj.2011.10.018. Review.

PMID:
22305831
26.

Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

Apisarnthanarax N, Wood GS, Stevens SR, Carlson S, Chan DV, Liu L, Szabo SK, Fu P, Gilliam AC, Gerson SL, Remick SC, Cooper KD.

Arch Dermatol. 2012 May;148(5):613-20. doi: 10.1001/archdermatol.2011.2797.

27.

AIDS-Related Non-Hodgkin's Lymphoma in Sub-Saharan Africa: Current Status and Realities of Therapeutic Approach.

Mwamba PM, Mwanda WO, Busakhala N, Strother RM, Loehrer PJ, Remick SC.

Lymphoma. 2012;2012. doi: 10.1155/2012/904367.

28.

Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.

Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson L, Abraham J, Remick SC, Hamadani M.

Hematol Oncol Stem Cell Ther. 2011;4(4):149-56. doi: 10.5144/1658-3876.2011.149.

29.

Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.

Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petros W, Mueller MD, Yu JJ.

Oncol Rep. 2012 Jan;27(1):286-92. doi: 10.3892/or.2011.1483. Epub 2011 Oct 3.

PMID:
21971700
30.

Barriers to recruitment of rural patients in cancer clinical trials.

Virani S, Burke L, Remick SC, Abraham J.

J Oncol Pract. 2011 May;7(3):172-7. doi: 10.1200/JOP.2010.000158.

31.

Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.

Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC.

J Oncol. 2011;2011:542358. doi: 10.1155/2011/542358. Epub 2011 Jun 12.

32.

The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting.

Hossain A, Chen A, Ivy P, Lenihan DJ, Kaltman J, Taddei-Peters W, Remick SC.

Heart Fail Clin. 2011 Jul;7(3):373-84. doi: 10.1016/j.hfc.2011.03.008. Epub 2011 May 20.

PMID:
21749889
33.

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton A, LoRusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy SP, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1439-47. doi: 10.1007/s00280-011-1637-5. Epub 2011 Apr 9.

34.

Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program.

Khanna R, Madhavan SS, Bhanegaonkar A, Remick SC.

J Womens Health (Larchmt). 2011 May;20(5):739-47. doi: 10.1089/jwh.2010.2298. Epub 2011 Mar 21.

PMID:
21417935
35.

Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study.

Putila J, Remick SC, Guo NL.

PLoS One. 2011 Feb 25;6(2):e17493. doi: 10.1371/journal.pone.0017493. Erratum in: PLoS One. 2011;6(3). doi: 10.1371/annotation/506974e6-6764-462c-b7d3-3cbd269c3d6c.

36.

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.

Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM.

Hematol Oncol. 2011 Dec;29(4):202-10. doi: 10.1002/hon.985. Epub 2011 Feb 28.

37.

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.

Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M.

Bone Marrow Transplant. 2012 Jan;47(1):146-8. doi: 10.1038/bmt.2011.18. Epub 2011 Feb 28. No abstract available.

PMID:
21358681
38.

A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.

Ricart AD, Ashton EA, Cooney MM, Sarantopoulos J, Brell JM, Feldman MA, Ruby KE, Matsuda K, Munsey MS, Medina G, Zambito A, Tolcher AW, Remick SC.

Cancer Chemother Pharmacol. 2011 Oct;68(4):959-70. doi: 10.1007/s00280-011-1565-4. Epub 2011 Feb 9.

PMID:
21305290
39.

Preliminary clinical and pharmacologic investigation of photodynamic therapy with the silicon phthalocyanine photosensitizer pc 4 for primary or metastatic cutaneous cancers.

Kinsella TJ, Baron ED, Colussi VC, Cooper KD, Hoppel CL, Ingalls ST, Kenney ME, Li X, Oleinick NL, Stevens SR, Remick SC.

Front Oncol. 2011 Jun 30;1:14. doi: 10.3389/fonc.2011.00014. eCollection 2011.

40.

The evolving role of statins in hematopoietic stem and progenitor cell transplantation.

Hamadani M, Craig MD, Gibson LF, Remick SC.

Am J Blood Res. 2011;1(1):57-64. Epub 2011 Jun 1.

41.

Combretastatin A4 phosphate: a novel vascular disrupting agent.

Nagaiah G, Remick SC.

Future Oncol. 2010 Aug;6(8):1219-28. doi: 10.2217/fon.10.90. Review.

PMID:
20799867
42.

Ocular surface squamous neoplasia in patients with HIV infection in sub-Saharan Africa.

Nagaiah G, Stotler C, Orem J, Mwanda WO, Remick SC.

Curr Opin Oncol. 2010 Sep;22(5):437-42. doi: 10.1097/CCO.0b013e32833cfcf9. Review.

43.

HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma.

Yu JJ, Fu P, Pink JJ, Dawson D, Wasman J, Orem J, Mwanda WO, Zhu H, Liang X, Guo Y, Petros WP, Mitsuyasu RT, Wabinga H, Remick SC.

PLoS One. 2010 May 17;5(5):e10477. doi: 10.1371/journal.pone.0010477.

44.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee.

J Natl Cancer Inst. 2010 May 5;102(9):596-604. doi: 10.1093/jnci/djq091. Epub 2010 Mar 29.

45.

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.

Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, Holleran JL, TenEyck CJ, Ivy SP, Belani CP.

J Clin Oncol. 2010 Mar 20;28(9):1520-6. doi: 10.1200/JCO.2009.25.0415. Epub 2010 Feb 22.

46.

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.

Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R; AIDS Malignancy Consortium.

Blood. 2010 Apr 15;115(15):3008-16. doi: 10.1182/blood-2009-08-231613. Epub 2009 Dec 18.

47.

Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literature.

Bhakta S, Flick SM, Cooney MM, Greskovich JF, Gilkeson RC, Remick SC, Ortiz J.

Clin Cardiol. 2009 Dec;32(12):E80-4. doi: 10.1002/clc.20685. Review.

48.

Bonnie's Bus--cancer disparities in West Virginia, philanthropy and opportunities to build lasting partnerships.

Roth R, Newhouse R, Robinson B, Faulkner S, Remick SC.

W V Med J. 2009 Oct;105 Spec No:68-72.

PMID:
19999270
49.

Building a statewide clinical trials network for cancer care in West Virginia.

Abraham J, Keresztury J, Azar J, Monga M, Bowers T, Jones MP, Tirona MT, Pollock J, Coonley C, Jubelirer S, Frame J, Fogg P, Getto M, Filburn S, Naim J, Lucas D, Petros W, Hall S, Remick SC.

W V Med J. 2009 Oct;105 Spec No:6-11.

50.

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.

Sweeney CJ, Takimoto C, Wood L, Porter JM, Tracewell WG, Darwish M, D'Andrea DM, Remick SC.

Cancer Chemother Pharmacol. 2010 Jul;66(2):345-56. doi: 10.1007/s00280-009-1169-4. Epub 2009 Nov 13.

PMID:
19911123

Supplemental Content

Loading ...
Support Center